New Psychoactive Substances: Which Biological Matrix Is the Best for Clinical Toxicology Screening?
- PMID: 35175247
- DOI: 10.1097/FTD.0000000000000974
New Psychoactive Substances: Which Biological Matrix Is the Best for Clinical Toxicology Screening?
Abstract
Background: Every year, more new psychoactive substances (NPSs) emerge in the market of the drugs of abuse. NPSs belong to various chemical classes, such as synthetic cannabinoids, phenethylamines, opioids, and benzodiazepines. The detection of NPSs intake using different types of biological matrices is challenging for clinical toxicologists because of their structural diversity and the lack of information on their toxicokinetics, including their metabolic fate.
Methods: PubMed-listed articles reporting mass spectrometry-based bioanalytical approaches for NPSs detection published during the past 5 years were identified and discussed. Furthermore, the pros and cons of using common biological matrices in clinical toxicology (CT) settings to screen for NPSs are highlighted in this review article.
Results: Twenty-six articles presenting multianalyte screening methods for use in the field of CT were considered. The advantages and disadvantages of different biological matrices are discussed with a particular view of the different analytical tasks in CT, especially emergency toxicology. Finally, an outlook introduces the emerging trends in biosamples used in CT, such as the exhaled breath.
Conclusions: Blood and urine represent the most common biological matrices used in a CT setting; however, reports concerning NPSs detection in alternative matrices are also available. Noteworthy, the selection of the biological matrix must depend on the clinician's enquiry because the individual advantages and disadvantages must be considered.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS.Bioanalysis. 2014 Aug;6(15):2083-107. doi: 10.4155/bio.14.168. Bioanalysis. 2014. PMID: 25322784 Review.
-
Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices.J Pharm Biomed Anal. 2019 Jan 30;163:170-179. doi: 10.1016/j.jpba.2018.10.011. Epub 2018 Oct 4. J Pharm Biomed Anal. 2019. PMID: 30316062 Review.
-
Comprehensive toxicological screening of common drugs of abuse, new psychoactive substances and cannabinoids in blood using supported liquid extraction and liquid chromatography-quadrupole time-of-flight mass spectrometry.J Anal Toxicol. 2023 Nov 1;47(8):656-667. doi: 10.1093/jat/bkad069. J Anal Toxicol. 2023. PMID: 37702353
-
Bioanalytical Methods for New Psychoactive Substances.Handb Exp Pharmacol. 2018;252:413-439. doi: 10.1007/164_2017_83. Handb Exp Pharmacol. 2018. PMID: 29374833
-
Recent trends in drugs of abuse metabolism studies for mass spectrometry-based analytical screening procedures.Anal Bioanal Chem. 2021 Sep;413(22):5551-5559. doi: 10.1007/s00216-021-03311-w. Epub 2021 Apr 1. Anal Bioanal Chem. 2021. PMID: 33792746 Free PMC article. Review.
Cited by
-
Comparison of reversed-phase, hydrophilic interaction, and porous graphitic carbon chromatography columns for an untargeted toxicometabolomics study in pooled human liver microsomes, rat urine, and rat plasma.Metabolomics. 2024 Apr 30;20(3):49. doi: 10.1007/s11306-024-02115-0. Metabolomics. 2024. PMID: 38689195 Free PMC article.
-
In Vitro and In Vivo Toxicometabolomics of the Synthetic Cathinone PCYP Studied by Means of LC-HRMS/MS.Metabolites. 2022 Dec 2;12(12):1209. doi: 10.3390/metabo12121209. Metabolites. 2022. PMID: 36557246 Free PMC article.
References
-
- EMCDDA. European Drug Report 2020. Publications of of the European Union; 2020. Available at: http://www.emcdda.europa.eu/edr2020_en . Accessed October 08, 2021.
-
- Flanagan RJ, Taylor A, Watson ID, et al. Analytical toxicology: overview. In: Fundamentals of Analytical Toxicology. Chichester, United Kingdom: John Wiley & Sons Ltd., 2008:1–19.
-
- Brent J, Burkhart K, Dargan P, et al. Critical Care Toxicology. Basel, Switzerland: Springer International Publishing, 2017.
-
- Meyer MR, Maurer HH. Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices—where do we stand today? Anal Chim Acta. 2016;927:13–20.
-
- Wagmann L, Richter LHJ, Kehl T, et al. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal Bioanal Chem. 2019;411:4751–4763.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous